arrow
H

Hannah Choe

the ohio state university comprehensive cancer center
H指数:24
被引数:2,157

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Itacitinib plus calcineurin inhibitor–based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 results

伊塔西替尼联合钙调神经磷酸酶抑制剂为基础的治疗预防移植物抗宿主病:GRAVITAS-119研究结果

2026-10-070
PRE
Reduced-Dose Post-Transplant Cyclophosphamide (PTCy 40-40) in Allogeneic Hematopoietic Cell Transplantation

异基因造血细胞移植中低剂量移植后环磷酰胺的应用(PTCy 40-40)

2026-08-230
PRE
The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHD

MAGIC复合应答:一种整合临床和生物标志物参数的急性GVHD新型终点指标

2025-08-190
OAAI
Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

急性GVHD第28天治疗反应标准的修订:JSTCT与MAGIC的合作研究

2025-07-030
OAAI
DHODH inhibition alters T cell metabolism limiting acute graft-versus-host disease while retaining graft-versus-leukemia response

DHODH抑制改变了T细胞代谢,限制了急性移植物抗宿主病,同时保留了移植物抗白血病反应。

2025-03-220
PRE
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

血液恶性肿瘤患者接受CAR T细胞疗法后的第二原发恶性肿瘤

2025-03-180
OA
Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation

供者年龄和供者巨细胞病毒血清状态对亲属供者异基因造血干细胞移植后结局的影响

2025-03-120
PRE
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group

移植物抗宿主病治疗期间的系列临床和生物标志物监测确定了不同的风险阶层,包括超低风险组

2025-01-010
PRE
Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

比较两种骨髓清除性全身照射(MAC-TBI)方案:用于成人血液系统恶性肿瘤异基因干细胞移植的1200 Cgy与800 Cgy TBI剂量比较

BLOOD
IF23.1
2024-11-050
PRE
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
2024-09-196
PRE
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
2024-06-282
OAAI
Amphiregulin, ST2, and REG3 α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
2024-06-140
OAAI